N = 598 | OS | PFS | ||||||
---|---|---|---|---|---|---|---|---|
p value | HR | 95%CI | p value | HR | 95%CI | |||
HBini | 0.010 | 0.995 | 0.991–0.999 | 0.013 | 0.995 | 0.992–0.999 | ||
HBlowest | 0.575 | 0.999 | 0.995–1.003 | 0.010 | 0.995 | 0.992–0.999 | ||
HBini ≤ 80 g/L | 40(6.7) | 0.012 | 1.608 | 1.109–2.332 | 0.065 | 1.371 | 0.981–1.916 | |
HBini > 80 g/L | 558(93.3) | |||||||
Metastases | ||||||||
Metastatic sites ≥3 | 127(21.2) | 0.033 | 1.268 | 1.020–1.577 | 0.015 | 1.289 | 1.050–1.583 | |
Metastatic sites < 3 | 471(78.8) | |||||||
Lymph node | 457(76.4) | 0.849 | 0.980 | 0.794–1.209 | 0.276 | 0.896 | 0.734–1.092 | |
Liver | 246(41.1) | 0.010 | 1.271 | 1.059–1.525 | 0.001 | 1.354 | 1.141–1.607 | |
Lung | 99(16.6) | 0.399 | 0.899 | 0.703–1.151 | 0.221 | 1.150 | 0.920–1.438 | |
Bone | 25(4.2) | 0.072 | 1.495 | 0.964–2.318 | 0.017 | 1.651 | 1.093–2.493 | |
Peritoneum | 67(11.20) | 0.181 | 0.821 | 0.651–1.096 | 0.771 | 0.960 | 0.729–1.264 | |
Chemotherapy regimen | ||||||||
Included paclitaxel | 239(40.0) | 0.116 | 1.160 | 0.964–1.397 | 0.018 | 1.232 | 1.037–1.463 | |
Included platinum | 61(10.2) | 0.290 | 0.849 | 0.626–1.150 | 0.734 | 0.985 | 0.748–1.296 | |
Number of cycles | < 0.001 | 0.916 | 0.894–0.940 | 0.006 | 0.97 | 0.948–0.991 | ||
Number of PTX3* | 0.023 | 0.937 | 0.885–0.991 | 0.940 | 1.002 | 0.955–1.051 | ||
Treatment response | ||||||||
Progressive disease | 188(31.4) | 0.041 | 1.223 | 1.008–1.484 | < 0.001 | 1.959 | 1.634–2.350 | |
Non-progressive disease | 410(68.6) | |||||||
HBdec | ||||||||
≥ 30 | 131(21.9) | 0.048 | 1.244 | 1.002–1.546 | < 0.001 | 1.594 | 1.302–1.951 | |
< 30 | 467(78.1) | |||||||
Transfusion | 87(14.5) | 0.778 | 1.038 | 0.802–1.342 | 0.492 | 1.085 | 0.860–1.367 | |
No transfusion | 511(85.5) | |||||||
Adjuvant chemotherapy | 170 | 0.735 | 1.010 | 0.954–1.070 | 0.470 | 0.981 | 0.931–1.034 |